Press Releases September 22, 2026 07:05 AM

OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations

OrthoPediatrics Announces Milestone of 1,000 PNP Tibia Nail Implantations, Expanding Pediatric Orthopedic Treatment

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
KIDS

OrthoPediatrics Corp. announced the implantation of its 1,000th Pediatric Nailing Platform (PNP) Tibia Nail, highlighting rapid adoption of its innovative pediatric-focused tibial nail system. The PNP Tibia System addresses treatment gaps for children with tibia fractures, featuring the only 7mm cannulated rigid tibial nail available, and is currently marketed in five countries with a European launch set for 2027.

OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations
KIDS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OrthoPediatrics surpassed 1,000 implantations of its Pediatric Nailing Platform (PNP) Tibia Nail, demonstrating strong market adoption.
  • The PNP Tibia System is uniquely designed for pediatric patients, including a 7mm rigid tibial nail for treating previously untreatable fractures.
  • The product is currently available in five markets, with planned expansion to Europe in 2027, indicating growth potential internationally.

WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the recent implantation of the 1,000th Tibia Nail using its latest Pediatric Nailing Platform (PNP).

The PNP Tibia System was designed to bring a world-class, pediatric-focused nailing system to surgeons, enabling the use of rigid tibial nails in pediatric patients.

OrthoPediatrics’ introduction of the 7mm cannulated rigid tibial nail, the only product of its size, enables surgeons to treat patients who have previously been untreatable with adult systems. In fact, nearly 20% of all nails implanted by OrthoPediatrics have been the smallest 7mm size available. The implant is available in 7mm-12mm diameters.

Joe Hauser, President of Trauma & Deformity, stated, “The rapid adoption of this system demonstrates that OrthoPediatrics is filling a critical void in implant offerings to our core customer. The surgeon design team and our OrthoPediatrics engineers were meticulous in developing a system purpose-built for the needs of pediatric patients, and it is proving to be a valuable tool in treating over 1,000 kids with tibia fractures.”

The system includes small instruments to access the intramedullary canal, smaller overall nails, fixation options designed to avoid the physis, and instrumentation supporting both traditional and suprapatellar approaches.

PNP Tibia is currently available in five markets, with a European launch planned for 2027.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Taylor
Gilmartin Group
[email protected]


Risks

  • Expansion into new markets like Europe involves regulatory, commercial, and operational risks which may affect adoption speed.
  • Competition from adult orthopedic implant manufacturers and other pediatric solutions may limit market penetration.
  • Dependence on surgeon adoption and the need for ongoing innovation to maintain competitive advantage in pediatric orthopedic devices.

More from Press Releases

Edible Garden Secures New Walmart Distribution Center Award, Expanding Fresh Herb Distribution in the Upper Midwest Sep 22, 2026 Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 Sep 22, 2026 BrewDog Launches ‘Under New Ownership’ Campaign, Marking a New Era of Fresh Energy, New Backing and Award-Winning Beer Sep 22, 2026 Aya Gold & Silver Reports High-Grade Drill Exploration Results at Boumadine Sep 22, 2026 Gogo and Insitu collaborate on Group 3 UAS connectivity Sep 22, 2026